Cardiff Oncology
CRDF
116 hedge funds and large institutions have $102M invested in Cardiff Oncology in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 17 reducing their positions, and 17 closing their positions.
226% more call options, than puts
Call options by funds: $3.03M | Put options by funds: $929K
194% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 17
6.39% more ownership
Funds ownership: 42.23% → 48.62% (+6.4%)
1% less funds holding
Funds holding: 117 → 116 (-1)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
17% less capital invested
Capital invested by funds: $122M → $102M (-$20.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$5.81M |
| 2 |
BlackRock
New York
|
+$3.96M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.28M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.72M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$3.81M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.21M |
| 3 |
Renaissance Technologies
New York
|
-$2.1M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.95M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$778K |
CRDF Hedge Fund Activity: Q1 2025 in Review
116 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2025, worth a combined $102M — down 17% from $122M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CRDF and 16 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 50 added.
The largest buyer was William Blair & Company, adding an estimated $5.81M. The largest seller was OrbiMed, cutting an estimated $3.81M.
- 116 institutional investors held Cardiff Oncology (CRDF) as of Q1 2025, down from 117 in Q4 2024.
- Funds reported $102M of Cardiff Oncology stock for Q1 2025, down 17% quarter-over-quarter.
- 16 funds opened new Cardiff Oncology positions in Q1 2025 and 17 closed out, a net change of -1 holder.
- The largest Cardiff Oncology buyer in Q1 2025 was William Blair & Company, an estimated $5.81M added.
- The largest Cardiff Oncology seller in Q1 2025 was OrbiMed, an estimated $3.81M sold.
Based on aggregated 13F filings for Q1 2025.